# CI2

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/ci2/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 54.5 |
| Citations | 4,521 |
| City | Prague |
| Country | CZ |
| Description | CI2 is a research organisation in Prague, CZ. OpenAlex records 7,716 works and 4,521 citations for it. 1,208 researchers list it as their most recent affiliation. |
| Homepage | http://ci2.co.cz/en |
| OpenAlex ID | https://openalex.org/I4210106832 |
| Researchers | 1,208 |
| ROR ID | https://ror.org/01h724050 |
| Type | nonprofit |
| Works | 7,716 |

## University papers

- [Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC](https://scholariq.org/papers/atezolizumab-for-first-line-treatment-of-metastatic-nonsquamous-nsclc/)
- [Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial](https://scholariq.org/papers/efficacy-and-safety-of-trastuzumab-deruxtecan-in-patients-with-her2-expressing/)
- [Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial](https://scholariq.org/papers/atezolizumab-plus-bevacizumab-and-chemotherapy-in-non-small-cell-lung-cancer/)
- [Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial](https://scholariq.org/papers/atezolizumab-in-combination-with-carboplatin-and-nab-paclitaxel-in-advanced/)
- [Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer](https://scholariq.org/papers/trifluridine-tipiracil-and-bevacizumab-in-refractory-metastatic-colorectal/)
- [Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i> -Mutated Advanced NSCLC](https://scholariq.org/papers/amivantamab-plus-lazertinib-in-previously-untreated-i-egfr-i-mutated-advanced/)
- [IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain](https://scholariq.org/papers/impower150-final-exploratory-analyses-for-atezolizumab-plus-bevacizumab-and/)

## University top topics

Showing 8 of 14.

- [Legal and Regulatory Analysis](https://scholariq.org/topics/legal-and-regulatory-analysis/)
- [Military Technology and Strategies](https://scholariq.org/topics/military-technology-and-strategies/)
- [Linguistic, Cultural, and Literary Studies](https://scholariq.org/topics/linguistic-cultural-and-literary-studies/)
- [Microbial Natural Products and Biosynthesis](https://scholariq.org/topics/microbial-natural-products-and-biosynthesis/)
- [Plant Disease Resistance and Genetics](https://scholariq.org/topics/plant-disease-resistance-and-genetics/)
- [Synthesis and Biological Activity](https://scholariq.org/topics/synthesis-and-biological-activity-2/)
- [Geochemistry and Geologic Mapping](https://scholariq.org/topics/geochemistry-and-geologic-mapping/)
- [Genomics and Phylogenetic Studies](https://scholariq.org/topics/genomics-and-phylogenetic-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.